Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

Novo Nordisk is involved in a clinical trial using the company’s GLP-1 analog diabetes drug Victoza to evaluate if the medicine can improve brain function and cognition in Alzheimer’s patients.

The toll from a new virus in China rose to six deaths and more than 300 cases as millions of Chinese prepared to travel for the Lunar New Year, heightening contagion risks.

Scientists at the Broad Institute of MIT and Harvard tested about 4,518 drugs on 578 human cancer cell lines, and discovered that almost 50 had previously unrecognized anti-cancer properties.

The U.S. Supreme Court rejected a bid by the Democratic-controlled House of Representatives and 20 Democratic-led states to fast-track consideration of their appeal seeking a definitive ruling that the Obamacare healthcare law does not violate the U.S. Constitution.

The U.S. Food and Drug Administration granted a priority review for GlaxoSmithKline plc’s Biologics License Application seeking approval of belantamab mafodotin (GSK2857916) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.